The 5 drugs tracked here made $27.1B of Pfizer’s 2025 revenue (43%) and lose US exclusivity by 2035. Since 2023, Pfizer has closed 2 acquisitions of $1B or more, worth $51.0B in total. Products from those deals brought in $3.46B in 2025.
Bars are each drug's 2025 sales as a share of Pfizer’s total revenue ($62.6B). Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Dec 2023 | SeagenSeagen 8-K, December 2023 | $43.0B | Oncology | Four approved cancer drugs (Padcev, Adcetris, Tivdak, Tukysa) and an antibody-drug conjugate pipelineEnterprise value.2025 sales: Padcev $1.94B, Adcetris $907M, Tukysa $463M, Tivdak $147M Pfizer FY2025 | Approved product |
| Nov 2025 | MetseraPfizer 10-Q, Q2 2026 | $8.0B | Cardiometabolic | Injectable and oral obesity drugs in clinical trialsPfizer's reported value, including $0.6B for CVRs that could pay up to $2.3B. | Pipeline only |
| 2 counted | $51.0B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Pfizer announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $6.3B | $43.0B |
| Cardiometabolic | $14.3B | $8.0B |
| Vaccines | $6.5B | – |
Pfizer has the most revenue at risk in cardiometabolic, but has spent the most on acquisitions in oncology. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Pfizer paid, not the sales it will bring in. Only one of the 2 companies it bought was already selling an approved product at closing (Seagen); the rest brought pipeline drugs whose sales are years away and may never arrive. The closest like-for-like figure is sales of the products Pfizer bought: $3.46B in 2025, against $27.1B of 2025 sales losing US exclusivity by 2037. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: Pfizer FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Pfizer’s announcement or filing in the table above.
See all 63 drugs on the patent cliff →Pfizer settled with Dexcel, Hikma and Cipla, extending the effective US patent expiry to 1 June 2031, subject to a case against Apotex. Pfizer had expected US sales to fall from 2029. Pfizer Q1 2026 results
Launch still waits on patents: the last listed Xtandi patent expires in August 2027. FDA Orange Book